Clinical trial
WHI Extended Follow-up (2024 update)
Last updated 2026-07-02· Last reviewed 2026-07-02· 1 min read
Reviewed by the Ultimate Longevity Bible editorial team. Educational reference — not medical advice. See disclaimer.
Trial arms
- CEE + MPA (women with intact uterus).
- CEE alone (women who had hysterectomy).
Original findings (2002–2007)
- CEE + MPA: increased breast cancer, coronary heart disease, stroke, VTE.
- CEE alone: increased stroke, VTE; no CHD signal; reduced breast cancer.
What extended follow-up refined
- The excess breast cancer signal from CEE + MPA persists but is smaller and formulation-specific (MPA drives it; CEE alone reduces risk).
- Age-stratified analyses show much more favourable risk-benefit for women initiating before age 60 or within 10 years of menopause onset.
- Bone-density protection is durable.
- Cognitive-decline and mortality outcomes are largely neutral in the appropriate initiation window.
Practical implications
- Transdermal oestradiol + micronised progesterone (modern regimen) is likely safer than the WHI's oral CEE + MPA — though this remains an inference from mechanism rather than direct RCT comparison.
- Symptomatic perimenopausal and menopausal women in the correct window are increasingly recognised as appropriate candidates.
- Estradiol — Biomarker.
- Hormone Therapy: Systemic vs Local — Comparison.
Related entries
HRT (menopause), Cardiovascular disease, Longevity for women.